Objective To study the relationship between growth hormone (GH) and microangiopathy in patients with diabetes mellitus in order to elucidate pathogenesis on microangiopathy in diabetics. Methods GH and insulin (INS) ...Objective To study the relationship between growth hormone (GH) and microangiopathy in patients with diabetes mellitus in order to elucidate pathogenesis on microangiopathy in diabetics. Methods GH and insulin (INS) were detected by radioimmunoassay, and blood sugar (BS) was detected by oxydase method. Results 138 NIDDM diabetics were examined. The concentration of serum GH in diabetics without microangiopathy (2.3±1.2 μg/L) was higher than in normal people (1.0±1.2 μg/L) and GH in diabetics with microangiopathy (5.74±1.94 μg/L) was higher than in diabetics without microangiopathy. The differences were significant ( P <0.01). As the history of diabetes went on, the level of GH in serum increased, and the incidence of microangiopathy increased too. The correlation of GH in serum with BS was parallel. The correlation of GH in serum with INS was not apparent. 27 IDDM diabetics were examined, their level of GH in serum (6.8±3.4 μg/L) was higher than that of NIDDM diabetics (4.6±1.8 μg/L). They were all patients with microangiopathy. Conclusion The rise of GH in serum may be an important pathogeny that causes microangiopathy in diabetics.展开更多
文摘Objective To study the relationship between growth hormone (GH) and microangiopathy in patients with diabetes mellitus in order to elucidate pathogenesis on microangiopathy in diabetics. Methods GH and insulin (INS) were detected by radioimmunoassay, and blood sugar (BS) was detected by oxydase method. Results 138 NIDDM diabetics were examined. The concentration of serum GH in diabetics without microangiopathy (2.3±1.2 μg/L) was higher than in normal people (1.0±1.2 μg/L) and GH in diabetics with microangiopathy (5.74±1.94 μg/L) was higher than in diabetics without microangiopathy. The differences were significant ( P <0.01). As the history of diabetes went on, the level of GH in serum increased, and the incidence of microangiopathy increased too. The correlation of GH in serum with BS was parallel. The correlation of GH in serum with INS was not apparent. 27 IDDM diabetics were examined, their level of GH in serum (6.8±3.4 μg/L) was higher than that of NIDDM diabetics (4.6±1.8 μg/L). They were all patients with microangiopathy. Conclusion The rise of GH in serum may be an important pathogeny that causes microangiopathy in diabetics.
